

Inflammatory myofibroblastic tumor mimicking lymphoma on ^{18}F -FDG PET/CT. Report of a case and review of the literature

Chao Ma MD, PhD,

Jing Lu MD,

Guoqiang Chen MD,

Weixing Wang MD,

Fu Su MD,

Xinhui Su MD, PhD

Department of Nuclear Medicine,
Zhongshan Hospital Xiamen
University, Xiamen, Fujian 361004,
P. R. China

Keywords: Inflammatory
myofibroblastic tumor
-Lymph node - ^{18}F -FDG PET/CT

Corresponding author:

Fu Su MD

Department of Nuclear Medicine,
Zhongshan Hospital Xiamen
University, 201 Hubin South Road,
Xiamen 361004, China.
Phone: 86-592-2292535. Fax: 86-
592-2993352.
sufuxm@sina.com

Xinhui Su, PhD, MD
Department of Nuclear Medicine,
Zhongshan Hospital Xiamen
University, 201 Hubin South Road,
Xiamen 361004, China.
Phone: 86-592-2993350. Fax: 86-
592-2993352.
suxinhui@163.com

Received:

4 January 2018

Accepted revised:

10 February 2018

Abstract

Inflammatory myofibroblastic tumor (IMT) is an uncommon neoplasm that has been described in various locations throughout the body, but is rarely observed in systemic lymph nodes. We present a case of a 63 years old woman with left inguinal lymphadenopathy accompanied by low-grade fever. Fluorine-18-fluoro-deoxyglucose positron emission tomography/computed tomography (^{18}F -FDG PET/CT) revealed abnormal higher ^{18}F -FDG uptake on the neck, axillar, pulmonary hilar, mediastinal, mesenteric, retroperitoneal, pelvic and inguinal lymph nodes. These findings led to an initial misdiagnosis of lymphoma. Final histological diagnosis revealed an IMT. The patient was treated with oral steroids. Ultrasound assessments showed a complete resolution of systemic enlarged lymph nodes at the end of 1 month of therapy. There has been no evidence of recurrence through 12 months of post-treatment monitoring. This case suggests that IMT should be considered as a possible differential diagnosis in apparent cases of lymphoma. Further, it indicates that steroid therapy may serve as an effective treatment for IMTs that systemically affect lymph nodes.

Hell J Nucl Med 2018;21(1):77-80

Epub ahead of print: 20 March 2018

Published online: 25 April 2018

Introduction

Inflammatory myofibroblastic tumor (IMT) was originally observed in lung and described by Bunn in 1939 [1]. It is an uncommon mesenchymal tumor of unknown etiology consisting of neoplastic myofibroblasts and a conspicuous inflammatory infiltrate, which can arise in a wide variety of anatomic locations throughout the body and typically occurs in children and young adults [2, 3]. Multiple terms have been used to describe this type of lesion, including inflammatory pseudotumor, fibrous xanthoma, plasma cell granuloma, pseudosarcoma, lymphoid hamartoma, myxoid hamartoma, and inflammatory myofibrohistiocytic proliferation [4]. These diverse terms reflect the uncertainty regarding the etiology of the lesion [1]. In 1954, Umiker and Iverson renamed this lesion as IMT because of its mimicry of the clinical, radiological, and histopathological signs of malignant neoplasm [5]. Inflammatory myofibroblastic tumor is a rare neoplasia, occurs most commonly in the lungs, liver and gastrointestinal tract [1], accounting for 0.04%-1.2% of all lung tumors [6]. To our knowledge, few cases only of IMT of systemic lymph nodes have been reported in the literature.

Conventional imaging modalities, such as ultrasound, computed tomography (CT), and magnetic resonance imaging, are commonly used as initial diagnostic technologies for tumor detection. However, their diagnostic capabilities to differentiate between benign and malignant lesions are limited [7]. Kim et al. (2009) have reported that clear radiologic differentiation of an abdominal IMT from other likely malignancies is difficult [8]. On the contrary, ^{18}F -FDG PET/CT has attracted increasing interest, and it has been used in the field of oncology, especially in diagnosis and treatment of lymphoma. Fluorine-18-FDG PET/CT imaging of IMT affecting lung and abdominal tissue have been represented in a limited number of studies [9, 10], whereas the ^{18}F -FDG PET/CT characteristics of primary IMT in lymph nodes have been even more rarely described. Herein, we present ^{18}F -FDG PET/CT findings in a case of IMT affecting lymph nodes in a systemic fashion, with the suggestion that clinicians consider this type of IMT as a differential diagnosis in apparent cases of lymphoma.

Case Report

A 63 years old women presented with a gradually increasing painless swelling in her left groin over the last 20 days accompanied by low-grade fever over the last 7 days, and was admitted to our Department of Oncology. She had unremarkable medical history with respect to trauma, cancer, tuberculosis, or surgery. On clinical examination, a firm, partly fixed, nodular mass, measuring 3.0cm in maximal diameter was founded in the left groin. Laboratory investigations revealed normal levels of red and white blood cells and unremarkable liver chemistry, including measurements of alanine aminotransferase and aspartate aminotransferase. Serum toluidine red unheated serum test (TRUST) and Treponema pallidum particle agglutination assay (TPPA) showed positive titers at 1:4 (normal range: negative) and 1:640 (normal range: 0-80), respectively. Epstein-Barr virus (EBV) (EBV-IgM and EBV nuclear antigen), antinuclear antibodies, and antiextractable-nuclear antigens were negative. C-reactive protein (CRP), at 10.93mg/L (normal range: 0-8) and D-dimer, at 2.24mg/L (normal range: 0-0.5) were slightly to moderately elevated. The initial ultrasound showed multiple enlarged lymph nodes in the inguinal area bilaterally with the largest node in the left groin (2.9cm length×1.5cm width).

The lymph node in the left groin underwent excisional biopsy. The specimen was fixed in 10% neutral buffered formalin. During macroscopic analysis of cut sections, we found a well-localized, well-demarcated, smooth discrete whitish fibrotic mass, measuring 4.0cm×2.5cm×2.0cm. The cut sections did not display infiltrative tumors in the intra-luminal compartment. No signs of necrosis, hemorrhage, or calcification were found.

During microscopic, histological analysis, we found that the tumor was composed mainly of collagenous fibrotic tissue and spindle-shaped myofibroblasts with diffuse infiltration of numerous inflammatory cells (Figure 1). Immunohistochemical staining of the tumor demonstrated the presence of smooth muscle actin (SMA) (Figure 2A), CD68 (KP-1) (Figure 2B), Ki-67 (Figure 2C), and the absence of anaplastic lymphoma kinase (ALK) (Figure 2D), desmin (Figure 2E), and P53 (Figure 2F). Two days after excisional biopsy of the lymph node in the left groin, ¹⁸F-FDG PET/CT (Siemens Biograph mCT; injection of 212.01MBq ¹⁸F-FDG) suggested systemic presence of the tumor, revealing multiple lymph nodes with intense ¹⁸F-FDG uptake as shown on the maximum intensity projection images.

In selected transaxial PET/CT slices, we found increased ¹⁸F-FDG accumulation in bilateral neck lymph nodes with a maximum standardized uptake value (SUVmax) of 4.67 (Figure 3A), bilateral axillary lymph nodes with SUVmax of 2.76 (Figure 3B), mediastinal lymph nodes with SUVmax of 5.70 (Figure 3C), pulmonary hilar lymph nodes with SUVmax of 5.70 (Figure 3D), mesenteric lymph nodes with SUVmax of 6.36 (Figure 3E), retroperitoneal lymph nodes with SUVmax of 3.42 (Figure 3F), pelvic lymph nodes with SUVmax of 4.85 (Figure 3G), and inguinal lymph nodes with SUVmax of 6.99

(Figure 3H & 3I). Nearly all lymph nodes exhibited uniformly intense ¹⁸F-FDG accumulation, and most of them showed signs of lymphadenectasis (from 1.8cm×1.4cm to 3.2cm×2.5cm in size).




Figure 1. Hematoxylin and eosin analysis of a lymph node in the left groin. (A) Low-powered magnification demonstrating prominent storiform and fascicular pattern collagenized areas and chronic inflammatory cells (magnification, ×100). (B) High-powered magnification demonstrating the presence of spindle shaped cells (myofibroblasts), mature plasma cells and lymphocytes (magnification, ×200).




Figure 2. Immunohistochemical analysis of a lymph node in the left groin, showing positive staining with SMA (A), CD68 (B), and Ki-67 (C), negative staining with ALK (D), desmin (E), and P53 (F) (magnification, ×100).




Figure 3. ¹⁸F-FDG PET/CT imaging of systemic IMT of the lymph nodes. (A) Neck lymph nodes; (B) Axillary nodes; (C) Mediastinal lymph nodes; (D) Pulmonary hilar lymph nodes; (E) Mesenteric lymph nodes; (F) Retroperitoneal lymph nodes; (G) Pelvic lymph nodes; (H) and (I) Inguinal lymph nodes. (J) MIP image.

Our ¹⁸F-FDG PET/CT findings suggested possible malignancy. However, the patient only reported a 7 day history of low-grade fever. Moreover, no signs of calcification or necrosis were found in the hypermetabolic lymph nodes, and no obvious pulmonary abnormalities were observed on CT scans. Based on patient's medical history and our imaging fin-

dings, lymphoma was first considered. Histology confirmed the final diagnosis of IMT. Because of the involvement of multiple lymph nodes, a complete excision of the affected lymph nodules was difficult to achieve.

The patient was treated with 0.5mg/kg of oral prednisone daily for 1 month. The ultrasound showed a complete resolution of systemic enlarged lymph nodes at the end of 1 month of therapy. There has been no evidence of recurrence through 12 months of post-treatment monitoring.

Our patient provided a written informed consent for the case report. The consent procedure was approved by the Ethics Committee of Zhongshan Hospital Xiamen University.

Discussion

According to the World Health Organization classification, IMTs are considered a mesenchymal neoplasm of intermediate malignant potential, since its histology is characterized by proliferation of fibroblasts and myofibroblasts combined with lymphocytes, plasma cells, eosinophils, and histiocytes [11]. Some IMTs can show however malignant biological behaviors, with a low risk for local recurrence (<5% of cases) and a moderate risk of distant metastasis [11].

The etiologic factors responsible for the development of IMT remain uncertain. Several hypotheses have been proposed, suggesting that it may be related to autoimmune or infectious mechanisms, noninfectious agents, or that it may be a true tumor [12]. It has been also reported, in 30% of patients with IMT, that the presence of the tumor was associated with recurrent infections caused by mycoplasma, nocardia, actinomycetes, EBV or human herpes virus species [6, 12]. In addition, trauma, abdominal surgery, and genetic factors have been associated with the presence of Inflammatory myofibroblastic tumor [13]. No previous history of trauma or abdominal surgery was reported in the presented case. Both TRUST and TPPA were positive, with elevated levels of CRP and D-dimers, suggesting an association with a syphilis infection.

The reported radiological characteristics of IMT have been variable and nonspecific [14]. Compared to conventional CT, ¹⁸F-FDG PET/CT examination can provide two types of information: morphological and metabolic. Several authors have reported cases of IMT exhibiting increased ¹⁸F-FDG uptake, as it is a metabolically active tumor mass [9,10]. IMT may be thus misdiagnosed as a neoplastic/recurrent disease when there is a prior history of cancer [10, 15]. Inflammatory myofibroblastic tumor positivity on ¹⁸F-FDG PET/CT is explained by the fact that ¹⁸F-FDG is absorbed by tumor cells, as well as macrophages, granulocytes, and inflamed tissues. The metabolic activity of IMT appears to be variable, with a SUVmax ranging from 3.8 to 20.8 [9], making distinction between IMT and malignant neoplasms impossible. In our case, the SUVmax was relatively intense, ranging from 2.76 to 6.99. Three factors may lead to increased glucose uptake degree within an IMT, such as high tumor cellularity, the presence of nuclear atypia and a relatively high proliferative index [9, 16]. Activated immune cells, including neutrophils and macrophages, over-express gluco-

se transporters that facilitate ¹⁸F-FDG uptake through the cell membrane. Therefore, the use of ¹⁸F-FDG PET/CT imaging in differentiating inflamed tissues from malignant lesions is limited, whereas it is useful for detecting metastasis and recurrent cancer, and for monitoring treatment response in patients with IMT. Kubo et al. (2012) reported a case of mediastinal ¹⁸F-FDG-avid IMT with multiple metastases in the thoracic vertebra and lymph nodes. After three cycles of chemotherapy, ¹⁸F-FDG PET/CT revealed tumor regression with significant reduction of ¹⁸F-FDG uptake in all lesions [17]. Dong et al. (2014) reported a case of ¹⁸F-FDG-avid lung IMT recurrent locally 7 months after resection [9].

Primary IMT in lymph nodes is a rare location with less than 10 cases reported so far. Its systemic occurrence in multiple lymph nodes is even less common. Gandhi et al. (2015) reported a case of IMT which presented as inguinal lymphadenopathy with fever. Initially, the patient was clinically misconstrued as lymphoma because cytology could not exclude a lymphoma. Immunohistochemical staining revealed IMT of the inguinal lymph nodes [19]. Important differential diagnosis might include lymphoma. Lymphoma also has no typical symptoms and may manifest with painless enlarged lymph nodes and fever. Therefore, differentiating between lymphoma and systemic IMT of the lymph nodes is difficult based solely on clinical and imaging manifestations. The key patholoanatomical differentiations of IMT are: spindle-shaped myofibroblastic cells and an intense inflammatory process, mainly involving lymphocytes and plasma cells [20]. The confirmation of the presence of SMA-positive myofibroblasts is important for the differential diagnoses from lymphoma that is confirmed SMA-negative [21]. Although controversial, ALK has been considered as a promising biomarker for improving the diagnostic accuracy of IMT [22]. ALK-protein positivity has been detected in 50 %-60% of cases with IMT due to ALK-gene rearrangement [23]. In our case, the tumor cells demonstrated expression of SMA, CD68 (KP-1) and Ki-67; they did not show expression of ALK, desmin, or P53. These results were consistent with previous reports [21-24].

The therapy for IMT includes surgical resection, steroids or non-steroidal anti-inflammatory drugs, radiation therapy, chemotherapy, and immunomodulators. These treatment modalities alleviated signs and symptoms with varying success rates [24]. Among these, complete surgical resection is the optimal therapeutic approach for IMT. Systemic steroid therapy yields rapid response, with 31%-78% of tumors disappearing completely in 24-48 hours; however, steroid therapy may be associated with a high relapse rate [25]. In this case, surgical resection was deemed not feasible due to multiple lesions, so we administered steroid therapy. The ultrasound showed a complete resolution of systemic enlarged lymph nodes at the end of 1 month of therapy. There has been no evidence of recurrence through 12 months of post-treatment monitoring. Our findings suggest that steroid therapy is a viable medical alternative when tumor resection is not feasible.

In conclusion, systemic IMT of the lymph nodes is a very rare tumor and its specific clinical manifestations and imaging findings have not been extensively described. Inflammatory myofibroblastic tumor easily mimics lymphoma as

both entities are ^{18}F -FDG avid. Histological examination is crucial for an accurate diagnosis of IMT. This case suggests that IMT should be considered as a differential diagnosis in lymphoma. Moreover, it suggests that oral steroid therapy may be a useful treatment for systemic IMT of the lymph nodes.

Acknowledgment

This work was supported by grants from the National Natural Science Foundation of China (NSFC) (81571707), Program for Training Young Talents of Fujian Health (2014-ZQN-ZD-35), Natural Science Foundation of Fujian (2015J01519), Science and Technology Bureau of Xiamen (3502Z20164021).

The authors declare that they have no conflicts of interest.

Bibliography

1. Brunn H. Two interesting benign tumors of contradictory histopathology: remarks on the necessity for maintaining the chest tumor registry. *J Thorac Surg* 1939; 9: 119-31.
2. Palaskar S, Koshti S, Maralingannavar M, Bartake A. Inflammatory myofibroblastic tumor. *Contemp Clin Dent* 2011; 2(4): 274-7.
3. Koyuncuer A. Inflammatory myofibroblastic tumor of the small-bowel mesentery: A case report of nonspecific clinical presentation and a review of the literature. *Int J Surg Case Rep* 2014; 5(12): 1214-7.
4. Oeconomopoulou A, de Verney Y, Kanavaki K et al. Inflammatory myofibroblastic tumor of the small intestine mimicking acute appendicitis: a case report and review of the literature. *J Med Case Rep* 2016; 10: 100.
5. Umiker WO, Iverson L. Post inflammatory tumors of the lung; report of four cases simulating xanthoma, fibroma, or plasma cell tumor. *J Thorac Surg* 1954; 28 (1): 55-63.
6. İçmeli ÖS, Alpaly LA, Gündoğuş B et al. Inflammatory myofibroblastic tumor: a rare tumor of the lung. *Eur Clin Respir J* 2014; 1.
7. Tamburrino D, Riviere D, Yaghoobi M et al. Diagnostic accuracy of different imaging modalities following computed tomography (CT) scanning for assessing the resectability with curative intent in pancreatic and periampullary cancer. *Cochrane Database Syst Rev* 2016; 9: CD01-1515. [Epub ahead of print].
8. Kim SJ, Kim WS, Cheon JE et al. Inflammatory myofibroblastic tumors of the abdomen as mimickers of malignancy: imaging features in nine children. *Am J Roentgenol* 2009; 193(5): 1419-24.
9. Dong A, Wang Y, Dong H et al. Inflammatory myofibroblastic tumor: FDG PET/CT findings with pathologic correlation. *Clin Nucl Med* 2014; 39(2): 113-21.
10. Dua SG, Purandare N, Pramesh CS et al. Fluorodeoxy glucose-avid endobronchial inflammatory myofibroblastic tumor mimicking bronchial malignancy: report of a case. *J Cancer Res Ther* 2011; 7(3): 340-3.
11. Fletcher CDM, Unni K, Mertens F. Pathology and Genetics, Tumors of Soft Tissue and Bone. World Health Organization Classification of Tumors. Lyon, France: IARC Press 2002: 91-3.
12. Hammas N, Chbani L, Rami M et al. A rare tumor of the lung: inflammatory myofibroblastic tumor. *Diagn Pathol* 2012; 7: 83.
13. Ntloko S, Gounden A, Naidoo M et al. Intestinal inflammatory myofibroblastic tumour. *S Afr J Surg* 2011; 49(4): 190-3.
14. Surabhi VR, Chua S, Patel RP et al. Inflammatory Myofibroblastic Tumors: Current Update. *Radiol Clin North Am* 2016; 54(3): 553-63.
15. Kawamura E, Habu D, Tsushima H et al. A case of hepatic inflammatory pseudotumor identified by FDG-PET. *Ann Nucl Med* 2006; 20(4): 321-3.
16. Yoon SH, Lee S, Jo KS et al. Inflammatory pseudotumor in the mediastinum: imaging with ^{18}F -fluorodeoxyglucose PET/CT. *Korean J Radiol* 2013; 14(4): 673-6.
17. Kubo N, Harada T, Anai S et al. Carboplatin plus paclitaxel in the successful treatment of advanced inflammatory myofibroblastic tumor. *Intern Med* 2012; 51 (17): 2399-401.
18. Oguz B, Ozcan HN, Omay B et al. Imaging of childhood inflammatory myofibroblastic tumor. *Pediatr Radiol* 2015; 45(11): 1672-81.
19. Gandhi A, Malhotra KP, Sharma S. Inflammatory myofibroblastic tumor of inguinal lymph nodes, simulating lymphoma. *J Cancer Res Ther* 2015; 11(3): 645.
20. Wang Z, Zhao X, Li K et al. Analysis of clinical features and outcomes for inflammatory myofibroblastic tumors in China: 11 years of experience at a single center. *Pediatr Surg Int* 2016; 32(3): 239-43.
21. Yu L, Liu J, Lao IW et al. Epithelioid inflammatory myofibroblastic sarcoma: a clinicopathological, immunohistochemical and molecular cytogenetic analysis of five additional cases and review of the literature. *Diagn Pathol* 2016; 11(1): 67.
22. Wu S, Xu R, Wan Q et al. Assessment of the potential diagnostic role of anaplastic lymphoma kinase for inflammatory myofibroblastic tumors: a meta-analysis. *PLoS One* 2015; 10(4): e0125087.
23. Sethi B, Pai T, Allam A, Epari S. Anaplastic lymphoma kinase-positive pulmonary inflammatory myofibroblastic tumor with sarcomatous morphology and distant metastases: An unusual histomorphology and behavior. *Indian J Pathol Microbiol* 2015; 58(4): 509-12.
24. Kiratli H, Uzun S, Varan A et al. Management of anaplastic lymphoma kinase positive orbitoconjunctival inflammatory myofibroblastic tumor with crizotinib. *JAAP OS* 2016; 20(3): 260-3.
25. Romero-Rojas AE, Diaz-Perez JA, Mastrodimos M et al. Primary intraocular inflammatory myofibroblastic tumor with anaplastic lymphoma kinase overexpression. *Int Ophthalmol* 2014; 34(3): 667-73.